Sera Prognostics announces study results and commercial partnership with Anthem
Sera announced results from a health and economic benefit evaluation of Sera’s PreTRM® test-and-treat strategy. The analysis was conducted in approximately 40,000 pregnant women who were members of the Anthem Health commercial insurance plan. Based on these data the authors conclude that use of the PreTRM® Test during pregnancy to identify women at risk of preterm birth, combined with evidence-based treatment, may substantially reduce preterm deliveries – as well as their short-term and long-term health and economic consequences in a representative population of commercially insured U.S. women. The work was done in collaboration with Anthem’s HealthCore subsidiary and is a part of Anthem’s broader Maternity and Community Health programs.
The company also announced a novel strategic commercial partnership with Anthem, Inc., the nation’s second largest health insurer with more than 40 million members nationwide, whose health plans cover more than 10% of U.S. pregnancies annually. Anthem will make PreTRM® tests available to pregnant members as part of a multi-year contract with Sera.